Johnson & Johnson

NYSE: JNJ
$164.16
-$0.66 (-0.4%)
Closing Price on September 20, 2024

JNJ Articles

A unit of Johnson & Johnson has announced that the FDA has approved its Stelara for the treatment of moderately to severely active Crohn's disease.
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
August 22, 2016: Markets opened lower again Monday as investors remain cautious ahead of the Fed’s Jackson Hole conference beginning Thursday. Fed Chairwoman Janet Yellen is scheduled to speak on...
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Johnson & Johnson, Lockheed Martin, MGIC Investment, TransCanada and Verizon Communications.
July 19, 2016: Markets opened mixed on Tuesday with the blue chips opening lower before bouncing higher. Unlike the S&P 500 Index and the Nasdaq Composite, which never traded higher at any moment...
As one of the largest health care companies on the market, Johnson & Johnson helps set a direction for the industry. Strength within its pharmaceutical segment helped push this company to new...
Johnson & Johnson is set to release its second-quarter earnings report before the markets open on Tuesday, a period in which it agreed to acquire a privately held company focused on hair care and...
One-third of the 30 Dow stocks are reporting quarterly results between July 18 and 22. The main question is whether these earnings can push the Dow to new highs.
With the Dow Jones Industrial Average hitting new all-time highs this past week, we have to wonder what we have in store going forward as earnings reporting ramps up.
Looking at what was a brief but massive fallout within broad markets, we are realizing that the Brexit provided a very attractive entry point into a fair number of industries. The Dow Jones...
ThinkstockAmerica’s largest companies tend to be located in major metropolitan areas. New York City alone is home to the headquarters of more than 70 of U.S.’s 1,000 largest public companies, the...
Standard & Poor's has now shown that the first quarter of 2016 saw a 12% rise in buyback spending to a whopping $161.4 billion.
Top executives, CEOs especially, are often measured by the business decisions they make and how their company is performing. Often just as important, however, is the company’s culture, which...
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.